Flag of the European Union EU Clinical Trials Register Help

Clinical trials for slovakia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44356   clinical trials with a EudraCT protocol, of which   7382   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,279 result(s) found for: slovakia. Displaying page 42 of 114.
    «« First « Previous 38  39  40  41  42  43  44  45  46  Next» Last»»
    EudraCT Number: 2021-001392-17 Sponsor Protocol Number: 19636 Start Date*: 2022-01-03
    Sponsor Name:Bayer AG
    Full Title: A randomized, double-blind, cross-over, placebo-controlled, multi-center, Phase 2a study to assess the safety and efficacy of BAY 2395840 in patients with diabetic neuropathic pain.
    Medical condition: Neuropathic pain associated with diabetic peripheral neuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10067547 Diabetic peripheral neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002063-87 Sponsor Protocol Number: Protocol Number 291-415 Start Date*: 2006-03-16
    Sponsor Name:PDL BioPharma, Inc
    Full Title: A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis
    Medical condition: Intravenous steroid-refractory ulcerative colitis (IVSR-UC)
    Disease: Version SOC Term Classification Code Term Level
    9.0 10045365 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) AT (Prematurely Ended) BE (Completed) CZ (Completed) DE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004611-13 Sponsor Protocol Number: G1T28-03 Start Date*: 2017-03-16
    Sponsor Name:G1 Therapeutics
    Full Title: Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
    Medical condition: Extensive-Stage Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) SI (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002904-13 Sponsor Protocol Number: 0019 Start Date*: 2006-11-01
    Sponsor Name:Theravance, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infec...
    Medical condition: Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus
    Disease: Version SOC Term Classification Code Term Level
    6.1 10052596 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Completed) SI (Completed) SK (Completed) LT (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000214-34 Sponsor Protocol Number: SYL1801_II Start Date*: 2022-10-08
    Sponsor Name:SYLENTIS S.A.U
    Full Title: A Randomized, Double masked, Parallel group, Dose-finding study to evaluate SYL1801 in patients with neovascular AMD
    Medical condition: Wet form of Neovascular Age-Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003662-41 Sponsor Protocol Number: MW-2004-11-02 Start Date*: 2005-11-24
    Sponsor Name:MediWound Ltd
    Full Title: Enzymatic Debridement in Burns Patients (Children & Adults): A Comparison to Standard of Care (Protocol MW 2004-11-02)
    Medical condition: Burn wounds defined as deep partial thickness or full thickness thermal burns.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SK (Completed) PT (Completed) CZ (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005586-13 Sponsor Protocol Number: AB12009 Start Date*: 2013-08-19
    Sponsor Name:AB SCIENCE
    Full Title: A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with s...
    Medical condition: Patients with severe COPD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SK (Prohibited by CA) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002161-19 Sponsor Protocol Number: 13062017-23-1 Start Date*: 2018-06-25
    Sponsor Name:Fakultní nemocnice Královské Vinohrady
    Full Title: Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction
    Medical condition: Cardiogenic shock in acute myocardial infarction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) FR (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002729-21 Sponsor Protocol Number: VUMC-ARC-GLORIA Start Date*: 2016-04-25
    Sponsor Name:VU University Medical Center
    Full Title: The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study Comparing the cost-effectiveness and safety of additional low-dose glucocorticoid in treatment strategies for elderly patients with...
    Medical condition: Rheumatoid artritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SK (Completed) FI (Prematurely Ended) PT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002569-16 Sponsor Protocol Number: I8H-MC-BDCU Start Date*: 2022-05-20
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared with Insulin Degludec in Participants with Type 2 Diabetes Currently ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) ES (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002235-60 Sponsor Protocol Number: NN9536-7545 Start Date*: 2023-02-24
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity and type 2 diabetes
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) SK (Completed) HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022168-11 Sponsor Protocol Number: TR-701-112 Start Date*: 2011-03-08
    Sponsor Name:Trius Therapeutics, Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of 6-Day Oral TR-701 Free Acid and 10-Day Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin...
    Medical condition: Acute Bacterial Skin and Skin Structure Infections
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10040872 Skin infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) LV (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000102-21 Sponsor Protocol Number: CAIN457F2309 Start Date*: 2011-08-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo- and active-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 1 year in...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) ES (Completed) DE (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003155-57 Sponsor Protocol Number: CQGE031B2204 Start Date*: 2015-11-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled study to investigate the efficacy and safety of 52 weeks treatment with QGE031 s.c. in Asthma Patients not adequately controlled by medi...
    Medical condition: Severe Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) IT (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) SK (Prematurely Ended) NL (Prematurely Ended) LU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017028-22 Sponsor Protocol Number: CSPP100A2365 Start Date*: 2010-06-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, 8 week study to evaluate the dose response, efficacy and safety of aliskiren in pediatric hypertensive patients 6-17 years of age.
    Medical condition: hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.1 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) FR (Ongoing) DE (Completed) SK (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-004540-23 Sponsor Protocol Number: CAEB071A2206 Start Date*: 2007-07-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus Neoral® in combination with Certican®, ...
    Medical condition: renal transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) IT (Completed) FR (Completed) BE (Completed) NL (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017723-26 Sponsor Protocol Number: Y5552120142 Start Date*: 2011-04-28
    Sponsor Name:Ipsen Pharma SAS
    Full Title: A phase III, prospective, multicentre, open label, extension study, to assess the long term safety and efficacy of repeated treatment of Dysport® intramuscular injection in the treatment of lower l...
    Medical condition: Leg Spasticity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10024132 Leg spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) SK (Completed) IT (Completed) PT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-005055-17 Sponsor Protocol Number: MRZ60201_3071_1 Start Date*: 2013-09-26
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Open-label, non-controlled, multicenter long-term study to investigate the safety and efficacy of Xeomin® (incobotulinumtoxin A, NT 201) for the treatment of spasticity of the lower limb(s) or of c...
    Medical condition: Lower limb and combined lower limb and upper limb spasticity due to cerebral palsy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10058977 Spastic paresis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) EE (Completed) SK (Completed) CZ (Completed) Outside EU/EEA FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-020467-21 Sponsor Protocol Number: WN25309 Start Date*: 2010-11-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Estudio en fase III multicéntrico aleatorizado, de 24 semanas, doble ciego, de grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de RO4917838 en pacientes estables c...
    Medical condition: Tratamiento de los síntomas negativos en pacientes con esquizofrenia tratados con antipsicóticos Treatment of negative symptoms for patients with schizophrenia treated with antipsychotics
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039626 Schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) LT (Prematurely Ended) LV (Prematurely Ended) SK (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002760-27 Sponsor Protocol Number: CAIN457F2309E1 Start Date*: 2012-09-27
    Sponsor Name:Novartis Pharma AG
    Full Title: A four year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) SK (Prematurely Ended) IT (Completed) BG (Prematurely Ended) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 38  39  40  41  42  43  44  45  46  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Aug 18 21:26:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA